治疗原发性腋窝多汗症的新药Sofpironium bromide

Sofpironium bromide:A new drug for primary axillary hyperhidrosis

于2020-09-25,日本药品和医疗器械综合管理机构正式批准5%的Sofpironium bromide凝胶用于治疗多汗症,这是日本首个批准用于治疗原发性腋窝多汗症的局部药物。Sofpironium bromide是由科研製薬株式会社研发的一种具有抗胆碱能作用的外用药物,可通过与汗腺中的M_(3)受体结合进而减少出汗。本文现从Sofpironium bromide的药理研究、药代动力学、临床研究、安全性等方面进行综述,以全面介绍该药的研究现状和已有成果。

On September 25,2020,Pharmaceuticals and Medical Devices Agency(PMDA)officially approved 5%Sofpironium bromide gel for the treatment of hyperhidrosis.This is the first topical product approved for the treatment of primary axillary hyperhidrosis in Japan.Sofpironium bromide is a topical drug with anticholinergic effect developed by Kaken Pharmaceutical Co.,Ltd.It can reduce sweating by binding to M_(3)receptor in the sweat gland that causes hyperhidrosis.The pharmacological study,pharmacokinetics,clinical research,and safety of Sofpironium bromide are reviewed to comprehensively introduce the research status and existing achievements of Sofpironium bromide.